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Introduction: Encyclopedic Tumor Analysis (ETA) is multi-analyte, molecular and functional interrogation to 
identify latent vulnerabilities in solid tumors which can then be targeted in organ- and label-agnostic combination 
treatment regimens. 
Case Presentation: We describe here a case of metastatic rectal cancer in a 61-year-old male who was progressed 
on all prior Standard of Care (SoC) treatment modalities including surgery, chemotherapy and radiotherapy. We 
addressed disease recurrence via personalized therapy guided by ETA which revealed characteristic molecular 
heterogeneity in primary and metastatic lesions in terms of single nucleotide variations (SNVs) and gene copy 
number variations (CNVs).  Notably, a novel TBL1XR1 (Exon1) – PIK3CA (Exon 2) gene fusion was identified 
in the tumor along with gene copy number gains in TERT, IGF-1R, MYC, FGFR1 and EGFR genes.  
Conclusion: ETA based molecular analysis with synchronous in vitro chemo-sensitivity profiling strategy helped 
to define de novo combinatorial therapy regimen of targeted and cytotoxic drugs which countered disease 
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Introduction 
Current Standard of Care (SoC) modalities for management of colorectal cancer (CRC) are surgery, 
chemotherapy, radiotherapy and targeted therapy mainly comprising anti-EGFR and anti-VEGF 
agents [1]. However, the treatment of metastatic CRC remains challenging with limited options after 
progression on SoC measures. Surgery is rarely feasible in metastatic disease and may be further 
restricted owing to patient’s health and other co-morbidities. Chemotherapy regimens with 
fluoropyrimidines (e.g., FOLFOX, FOLFIRI, FOLFIRINOX) which form the backbone of initial line 
therapies have limited utility in advanced refractory cancers with onset of resistance [2]. There appears 
to be limited utility of tyrosine kinase inhibitors (TKI) in CRC; Regorafenib, though indicated in SoC 
has low response rates. The use of anti-EGFR monoclonal antibody (mAb) Cetuximab is restricted to 
RAS wild type CRC, that too to left sided CRC where outcomes are better than right sided CRC [1]. 
EGFR inhibitors in combination with chemotherapy agents have shown limited efficacy in treatment 
of advanced CRC and the clinical use of such combinations are not common [3]. Finally, though 
Checkpoint Inhibitor Therapies (CIT) are approved for advanced CRC, these are limited to use in a 
setting of deficient mismatch repair (dMMR) / high microsatellite instability (MSI-high) / high tumor 
mutation burden (TMB), the prevalence rates of which have been reported to be <5% in colorectal 
cancers [4]. 
Molecular heterogeneity accounts for the large variations in prognosis and response to 
chemotherapy in (CRC) patients [5]. Presently, molecular investigations in CRC are restricted to 
variations in RAS and RAF for the purposes of prognostication. A recent effort identified 4 consensus 
molecular subtypes of biological relevance that were associated with different patient outcomes (CRC 
ESMO guidelines) [6].  However, such investigations have limited therapeutically actionable 
relevance in CRC. Multi-gene variant profiling panels for Next Generation Sequencing (NGS) have no 
application in SoC, and are considered for personalized or label-agnostic therapy selection as 
physician’s choice of treatment.  
We have previously described the clinical benefits of a multi-analyte, molecular and 
functional interrogation (ETA: Encyclopedic Tumor Analysis) to identify latent vulnerabilities in solid 
tumors which can then be targeted in organ- and label-agnostic combination treatment regimens [7-8]. 
In the present case report, we describe the case of an advanced refractory metastatic rectal cancer 
where personalized de novo combination regimen based on the findings of ETA yielded durable 
response. 
Case presentation 
The case described in this manuscript is a retrospective observational report of a single patient who 
opted to receive ETA-guided personalized treatment [7]. The patient consented for publication of 
deidentified data and results.  
Clinical history of this case is traceable to 2007 when the patient was diagnosed with 
Adenocarcinoma of the Rectum. The patient underwent abdominoperineal resection followed by 
standard dose chemotherapy with FOLFOX followed by external beam radiotherapy (EBRT) and 2 
fractions of high dose-rate (HDR) brachytherapy. Limited molecular profiling indicated that the tumor 
was KRAS wild-type (wt). The patient was asymptomatic for 4 years until recurrence was detected in 
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underwent radiofrequency ablation (RFA) in July 2011 as well as in Dec 2011, both of which showed 
complete metabolic response. Between 2012 and 2017, the patient reported recurrent urinary 
symptoms associated with periprostatic nodules for which he underwent RFA and other palliative 
procedures.  
Between February 2016 and February 2017, follow-up PET-CT scans documented increase 
in size of the persistent mass in retro-prostatic region which was infiltrating the base of urinary bladder 
along with perilesional necrotic deposits. Between February and August 2017, the patient was 
administered 6 cycles of FOLFIRI. A subsequent PET-CT scan in September 2017 showed increase in 
size of the necrotic retro-prostatic lesion which was extending into the obturator muscles and also 
infiltrating into the base of urinary bladder.  
A detailed exploratory workup in December 2017 via cystoscopy revealed necrosis in the 
prostatic fossa and evidence of cystitis. A whole-body PET-CT scan revealed further increase in tumor 
activity in the retroprostatic area along with evidence of necrosis along with persistent pelvic and 
inguinal lymphadenopathy. The patient was administered oral Tab Capecitabine (500 mg, 3 – 0 – 2 
daily) until March 2018, when a follow-up PET-CT revealed further increase in the size of the tumor, 
stemming from the retroprostatic site, involving the anorectal and pre-sacral regions adjacent to the 
base of urinary bladder, and extension of the lesion into bilateral obturator muscles along with 
metastatic iliac lymph nodes.  
Encyclopedic tumor analysis and personalized regimen  
In March 2018, the patient underwent a biopsy at the left inguinal node to obtain tumor tissue sample. 
The freshly biopsied tissue sample along with 15 mL of peripheral blood was provided to the study 
sponsor to perform ETA. Evaluation of mononucleotide repeat markers (NR-21, BAT-26, BAT-25, 
NR-24, MONO-27) in tumor tissue DNA showed stable microsatellites (MS-S). There were no 
detectable actionable or significant gene variations in tumor tissue by NGS; APC p.L1489fs*18 
variant (MAF 3.7%) was detected in NGS profiling of mutations in cell free tumor DNA (ctDNA) 
(Table 1). Differential gene expression profiling of the tumor transcriptome indicated significant 
overexpression of CYP17A1 indicating potential benefit from Abiraterone. In vitro chemo-resistance / 
sensitivity profiling of viable tumor cells indicated sensitivity towards several drugs including 
Methotrexate and Vinorelbine. Based on these findings the patient received a combination regimen of 
Methotrexate (70 mg; D1 and D8, 21-day cycle), Vinorelbine (40 mg; D1 and D8, 21-day cycle) and 
Abiraterone (250 mg, 1 OD), between March and September 2018 (7 cycles). Radiological follow-up 
(PET-CT) between March and September 2018 showed stable disease indicating that the treatment 
regimen had effectively halted further disease progression for up to 6 months along with stable serum 
CEA and CA19-9 levels. The regimen was well tolerated with minimal toxicity profile. Therapy 
related Adverse Events (AEs) were moderate (Grade II), transient and included Fatigue, Anorexia and 
Mucositis, all of which were clinically managed.   
In September 2018, increase in serum CEA levels (278 ng/ml) was observed even though 
there were no radiological or clinical indications of progression. The patient underwent a second 
biopsy to obtain tumor tissue from the Pelvic mass for ETA re-evaluation of the tumor. NGS mutation 
profiling of ctDNA showed persistence of the previously detected APC.pL1489fs*18 mutation (MAF 
1.9%) and emergence of new mutations in TP53. NGS mutation profiling of tumor tissue DNA 
revealed other single nucleotide variations (SNV) in TP53 p.T125T (MAF 66%), NOTCH3 p.R1190C 
(MAF 18%) and ATR p.R177* (MAF 3.9%) as well as copy number alterations (CNA, gain) in TERT 




Bose C et al. American Journal of Cancer Case Reports                        2021, 9:1-8                                                       Page 4 of  8 
Ivy Union Publishing | http: //www.ivyunion.org                                                                      March 10, 2021 | Volume 9, Issue 1  
showed overexpression of MMP7, MMP9, VEGFA, MAPK15, PTGS2 gene transcripts. Notably, a 
TBL1XR1-PIK3CA (T1:P2) gene fusion (209 transcript reads) was also detected in tumor tissue 
(Table 1). In vitro chemosensitivity profiling of viable tumor cells indicated low response towards 
Vinorelbine and Methotrexate, but increased response towards Pemetrexed.  
 
Table 1 Molecular alterations identified after encyclopaedic tumor analysis (ETA) of blood and tumor 
tissue samples. 
















APC p.L1489fs*18 MAF 3.7% ctDNA NGS 
CYP17A1  Overexpression  10 fold tissue Transcriptome 
IL-6 Overexpression  5 fold tissue Transcriptome 
MAP2K2 Overexpression  2.2 fold tissue Transcriptome 














APC p.L1489fs*18 MAF 3.7% ctDNA NGS 
TP53 p.C141Y MAF 0.9% ctDNA NGS 
TP53 p.V216M MAF 0.2% ctDNA NGS 
TP53 p.T125T MAF 66% tissue NGS 
NOTCH3 p.R1190C MAF 18% tissue NGS 
ATR p.R177* MAF 3.9% tissue NGS 
TERT CNV 17 gain tissue NGS 
IGF1R CNV 15 gain tissue NGS 
MYC CNV 14 gain tissue NGS 
FGFR1 CNV 9 gain tissue NGS 
EGFR CNV 8 gain tissue NGS 
TBL1XR1 – 
PIK3CA 
Fusion (T1:P2) 209 reads tissue NGS 
MMP7 Overexpression 9.9 fold tissue Transcriptome 
MMP9 Overexpression 3.7 fold tissue Transcriptome 
MAPK15 Overexpression 4.6 fold tissue Transcriptome 
VEGFA Overexpression 4.2 fold tissue Transcriptome 
IL-6 Overexpression 2.4 fold tissue Transcriptome 
PTGS2 Overexpression 2.2 fold tissue Transcriptome 
 
CHP – Cancer hotspot panel; NGS – Next Generation Sequencing; MAF – Mutant allele frequency; 
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Based on these findings, the patient was advised a combination regimen of Cetuximab 
(EGFR gain), Everolimus (chemo-sensitivity and TBL1XR1-PIK3CA fusion) and Pemetrexed 
(chemo-sensitivity). The patient was administered weekly Cetuximab (700 mg loading dose, 450 mg 
maintenance dose), Pemetrexed (500 mg, 21 day cycle) and Everolimus (5 mg, 1 OD) between 
October 2018 to March 2019. Administration of this regimen led to Partial Response (PR) during the 
same period (shown in Figure 1). There were no significant therapy related AEs with the exception of 
transient Anemia (Grade 3) as well as transient Anorexia and Fatigue, both Grade 2.  
 
 
Figure 1 Significant regression of malignant rectal mass revealed in positron emission tomography-
computed tomography (PET-CT) transverse sections. Compare follow-up scan after ETA guided therapy in right 
panel (B) Vs baseline scan left panel (A). 
 
Follow-up radiological data for the patient was available until April 2019, following which 
only telephonic follow-up data was available. During a recent (May 2020) telephonic follow-up, the 
patient was surviving and asymptomatic. However, therapy and disease status are presently unknown. 
Discussion 
The present study describes the case of an advanced refractory colorectal cancer where ETA revealed 
latent molecular and functional vulnerabilities that could be targeted with personalized de novo 
combination regimens. Prior lines of therapy received by this patient were based on SoC and included 
locoregional (surgery, RFA, EBRT) as well as systemic (FOLFOX, FOLFIRI, Capecitabine) 
treatments. The inability of prior treatments to yield objective and durable response highlights the 
limitations of SoC approaches to treat cancers, especially those which are advanced and refractory. 
Such futile treatment are also associated with accumulated adverse effects which thus indirectly 
increase the costs of cancer care with no benefits to patient. This is a common dilemma faced by 
oncologists during routine clinical practice where treatments are assigned on the basis of limited 
profiling or sidedness and lead to varying outcomes.  
Administration of the first iteration of ETA guided treatment regimen to the patient was 
beneficial in immediately halting further progression of the tumor. The use of Abiraterone [9] in this 
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Objective Response (OR) was not achieved, this regimen yielded a PFS of 6 months. Gene copy 
number gain of TERT , MYC and FGFR1 genes in subsequently biopsied tumor tissue indicates 
variations associated with poor prognosis in CRC [10-12]. The gain of EGFR gene copy number 
indicated potential benefit from Cetuximab, while gain of IGF-1R gene copy number indicated 
potential resistance to Cetuximab [13]. The tumor was found to harbour a novel gene fusion: 
TBL1XR1-PIK3CA since it has been reported to drive activation of PIK3CA [14]. Based on these 
findings, combination regimen included Cetuximab and Everolimus to achieve tandem targeting of 
multiple (EGFR, mTOR) pathways to improve treatment efficacy and Pemetrexed based on in vitro 
functional vulnerability. This multi-targeting de novo combination regimen led to durable partial 
response with significant regression in malignant rectal mass (shown in Fig. 1). The response to 
combination regimen is remarkable since recent clinical trials in metastatic KRAS-wt CRC have 
shown no benefit from the combination of anti-EGFR and anti-IGF1-R therapies over anti-EGFR 
monotherapy [15-16].  
Traditional integration of univariate molecular data of the tumor into clinical practice have 
limited benefits in CRC.  Similarly prior studies considering molecular indications have focussed on 
use of single agents such as Cetuximab in the NCI CCTG CO 17 trial [17], anti-EGFR antibody [17-
23], or anti-VEGF Bevacizumab [20] despite possible availability of multiple indications. The utility 
of patient-specific combination therapies in advanced cancers has remained largely unexplored except 
the RESILIENT trial [7]. The present case study provides evidence of benefit to patients in routine 
clinical practice from combination treatment strategies guided by multi-analyte tumor profiling.  
Conclusion 
This trajectory of response in this case of recurrent metastatic rectal cancer proves utility of ETA 
guided personalized therapy and superiority of such treatments over SoC regimens. Personalized 
combination regimen in this patient was based on de novo patient-derived evidence and was associated 
with improved treatment efficacy, response rates and survival. It is pertinent to mention that though 
Cetuximab was approved by the FDA approval for CRC in 2004, the same could not be administered 
to the patient owing to non-availability in India. Though it was considered for administration at a later 
date, the decision to avoid it was based on the presence of potential resistance mechanism (IGF1R 
copy gain). 
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